ABBV Form 4: Director holdings rise to 10,151 stock units

Rhea-AI Filing Summary

Robert J. Alpern, an AbbVie director, reported a Form 4 disclosing a non‑derivative acquisition on 09/30/2025 of 33 stock equivalent units credited at a per‑unit value of $231.54. The filing states these units are director fees credited to grantor trust accounts established by Abbott Laboratories and AbbVie and that AbbVie account units are payable in cash generally at age 65 or upon retirement from AbbVie’s board. The report shows a total beneficial ownership balance of 10,151 stock equivalent units (including amounts from dividend reinvestment). The Form 4 was signed by an attorney‑in‑fact on 10/02/2025.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Alpern Robert J

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Equivalent Units	33	$231.54	$8K

Holdings After Transaction: Stock Equivalent Units — 10,151 shares (Direct)

Footnotes (1)

1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Alpern Robert J

(Last) (First) (Middle)

1 N. WAUKEGAN ROAD

(Street)

NORTH CHICAGO IL 60064

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AbbVie Inc. [ ABBV ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Equivalent Units	$231.54	09/30/2025		A		33		(1)	(1)	Common Stock	33	$231.54	10,151(2)	D

Explanation of Responses:

1. Director fees credited to stock equivalent unit accounts under grantor trusts established by the director at Abbott Laboratories and AbbVie. The stock equivalent units in the Abbott account will be paid, in cash, generally at age 65 or upon retirement from Abbott's board, and the stock equivalent units in the AbbVie account will be paid, in cash, generally at age 65 or upon retirement from AbbVie's board. The stock equivalent units in each account earn the same return as if the fees were invested in AbbVie stock.

2. Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature.

	/s/ T.O. Odutayo, Attorney-in-Fact for Robert J. Alpern	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AbbVie director Robert J. Alpern report on Form 4 (ABBV)?

He reported acquisition of 33 stock equivalent units on 09/30/2025, credited at $231.54 per unit.

How many total stock equivalent units does Robert J. Alpern beneficially own according to the filing?

The filing shows a total balance of 10,151 stock equivalent units, which includes dividend reinvestment amounts.

What is the nature and payout timing of the stock equivalent units?

Units are director fees held in grantor trusts; AbbVie account units are paid in cash generally at age 65 or upon retirement from AbbVie’s board.

When was the Form 4 transaction dated and when was the form signed?

The transaction date is 09/30/2025 and the Form 4 was signed by an attorney‑in‑fact on 10/02/2025.

Are the stock equivalent units actual shares or cash‑settled?

The filing explains the stock equivalent units will be paid in cash when payable, and they earn returns as if invested in AbbVie stock.